A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

NCT02659020 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab
DRUG: Gemcitabine
DRUG: Docetaxel
DRUG: Placebo

Sponsor

Eli Lilly and Company